|
Delaware
|
| |
81-5266573
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(I.R.S. Employer
Identification Number) |
|
|
Mitchell S. Bloom, Esq.
John Mutkoski, Esq. Sam Zucker, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, Massachusetts 02210 (617) 570-1000 |
| |
Jonathan Young, Ph.D., J.D.
Co-Founder and Chief Operating Officer Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488 |
|
| Large accelerated filer ☐ | | | Accelerated filer ☐ | | | Non-accelerated filer ☒ | | |
Smaller reporting company
☒
|
|
| | | | | | | | | |
Emerging growth company
☒
|
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Title of Each Class of
Securities to be Registered |
| | |
Amount
to be Registered(1) |
| | |
Proposed
Maximum Offering Price Per Unit(2) |
| | |
Proposed
Maximum Aggregate Offering Price(3) |
| | |
Amount of
Registration Fee(4) |
| ||||||||||||
Common Stock, $0.0001 par value per share(5)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Preferred Stock, $0.0001 par value per share(6)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Debt Securities(7)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Warrants(8) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Units(9) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Total Offering
|
| | | | $ | 300,000,000 | | | | | | | N.A. | | | | | | $ | 300,000,000 | | | | | | $ | 38,940 | | |
Total Registration Fee
|
| | | | | | | | | | | | | | | | | | $ | 300,000,000 | | | | | | $ | 38,940 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 13 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 23 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | | |
| | | | 28 | | |
|
SEC registration fee
|
| | | $ | 38,940 | | |
|
FINRA filing fee
|
| | | | 45,500 | | |
|
Legal fees and expenses
|
| | | | * | | |
|
Accounting fees and expenses
|
| | | | * | | |
|
Printing fees and expenses
|
| | | | * | | |
|
Transfer agent and trustee fees
|
| | | | * | | |
|
Miscellaneous
|
| | | | * | | |
|
Total
|
| | | $ | * | | |
|
Name
|
| |
Title
|
| |
Date
|
|
|
/s/ Andrew Cheng
Andrew Cheng, M.D., Ph.D.
|
| |
Director, President, and Chief Executive Officer
(Principal Executive Officer) |
| |
July 1, 2020
|
|
|
/s/ William White
William White, J.D.
|
| |
Executive Vice President, Chief Financial Officer
and Head of Corporate Development (Principal Financial Officer and Principal Accounting Officer) |
| |
July 1, 2020
|
|
|
/s/ Kevin Bitterman
Kevin Bitterman, Ph.D.
|
| |
Director
|
| |
July 1, 2020
|
|
|
/s/ Seth L. Harrison
Seth L. Harrison, M.D.
|
| |
Director
|
| |
July 1, 2020
|
|
|
/s/ Jane P. Henderson
Jane P. Henderson
|
| |
Director
|
| |
July 1, 2020
|
|
|
/s/ Tomas J. Heyman
Tomas J. Heyman
|
| |
Director
|
| |
July 1, 2020
|
|
|
/s/ Mark Iwicki
Mark Iwicki
|
| |
Director, Chairperson
|
| |
July 1, 2020
|
|
|
/s/ Graham Walmsley
Graham Walmsley, M.D., Ph.D.
|
| |
Director
|
| |
July 1, 2020
|
|